NVO
Novo Nordisk A/SNYSEHealthcare$36.98+1.36%OpenMarket Cap: $164.32B
As of 2026-04-06
Valuation
P/E (TTM)
10.28
PEG
1.35
P/B
5.42
P/S
3.41
EV/EBITDA
7.20
DCF Value
$76.84
FCF Yield
5.3%
Div Yield
5.0%
Margins & Returns
Gross Margin
81.0%
Operating Margin
41.3%
Net Margin
33.1%
ROE
61.1%
ROA
24.8%
ROIC
29.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $78.43B | 80.9% | $31.62B | $26.65B | $6.04 | — |
| FY 2025 | $297.20B | 80.3% | $129.83B | $98.50B | $23.03 | $1.23 |
| Q3 2025 | $74.98B | 76.1% | $23.68B | $20.01B | $4.50 | $0.41 |
| Q2 2025 | $76.86B | 83.3% | $33.45B | $26.50B | $5.96 | $0.82 |
| Q1 2025 | $78.09B | 83.5% | $38.79B | $29.03B | $6.53 | $0.82 |
| Q4 2024 | $85.68B | 84.8% | $36.74B | $28.23B | $6.33 | — |
| FY 2024 | $290.40B | 84.7% | $128.34B | $100.99B | $22.63 | $1.03 |
| Q3 2024 | $71.31B | 84.1% | $33.82B | $27.30B | $6.12 | $0.36 |
| Q2 2024 | $68.06B | 84.9% | $25.93B | $20.05B | $4.49 | — |
| Q1 2024 | $65.35B | 84.8% | $31.85B | $25.41B | $5.68 | $0.66 |
| Q4 2023 | $65.86B | 84.8% | $26.77B | $21.96B | $4.91 | — |
| FY 2023 | $232.26B | 84.6% | $102.57B | $83.68B | $18.62 | $2.06 |